Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Volume 19, Number 1—January 2013

Dispatch

Klebsiella pneumoniae Antimicrobial Drug Resistance, United States, 1998–2010

Guillermo V. Sanchez, Ronald N. Master, Richard B. Clark, Madiha Fyyaz, Padmaraj Duvvuri, Gupta Ekta, and Jose BordonComments to Author 
Author affiliations: Author affiliations: George Washington University, Washington, DC, USA (G.V. Sanchez); Quest Diagnostics Nichols Institute, Chantilly, Virginia, USA (R.N. Master, R.B. Clark); Providence Hospital, Washington (M. Fyyaz, P. Duvvuri, G. Ekta, J. Bordon)

Main Article

Figure 2

Prevalence of antimicrobial cross-resistance among imipenem-resistant Klebsiella pneumoniae isolates, United States, 2010. TET, tetracycline; AMK, amikacin; GEN, gentamicin; CPM, cefepime; SXT, trimethoprim/sulfamethoxazole; CRO, ceftriaxone; TOB, tobramycin; CIP, ciprofloxacin; TZP, piperacillin/tazobactam; CAZ, ceftazidime; ATM, aztreonam.

Figure 2. . Prevalence of antimicrobial cross-resistance among imipenem-resistant Klebsiella pneumoniae isolates, United States, 2010. TET, tetracycline; AMK, amikacin; GEN, gentamicin; CPM, cefepime; SXT, trimethoprim/sulfamethoxazole; CRO, ceftriaxone; TOB, tobramycin; CIP, ciprofloxacin; TZP, piperacillin/tazobactam; CAZ, ceftazidime; ATM, aztreonam.

Main Article

Page created: December 20, 2012
Page updated: December 20, 2012
Page reviewed: December 20, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external